After the virus infects the body, it can stimulate the body to produce a certain number of neutralizing antibodies, so as to achieve the effect of preventing the body from re-infecting the same virus. The preventive vaccine developed based on this principle can induce the body to produce a sufficient amount of neutralizing antibodies to resist viral infection. Vaccination plays an important role in the prevention and control of viral infectious diseases. An effective vaccine can quickly induce high-titer neutralizing antibodies in the body. The level of neutralizing antibodies is the key index to measure the immune protection effect of the vaccine. At present, in addition to the traditional plaque inhibition method and cytopathy method based on live viruses, there are many new methods combined with the development of new technology, such as the detection method of recombinant live viruses containing reporter genes and the detection method of neutralizing antibodies based on pseudovirus.
Example
Screening of neutralizing antibodies against ZIKV by the Nt-ELISPOT
(A) Representative well of neutralizing antibodies screened by the Nt-ELISPOT. Three neutralizing antibodies, 7F3, 12F12 and 8A6, were screened by Nt-ELISPOT. Unrelated antibody- and PBS-treated wells were used as controls. The concentration of the mAbs was 125 μg/mL. The ZIKV-infected cells were labeled in blue with HRP-conjugated 11C11. The number of spots was counted by an ImmunoSpot analyser and recorded in the upper right corner of the image. (B) The IC50 of the mAbs 7F3, 12F12 and 8A6 (an initial concentration of 1 mg/mL) detected by the Nt-ELISPOT. Antibodies were diluted serially in two-fold dilutions.
Reference
Li, Shuxuan; zhao, huan; yang, hongwei; Hou, Wangheng; Cruz-cosme, Ruth; Cao, Ruiyuan; chen, chunye; wang, wei; xu, longfa; Zhang, Jun; Zhong, Wu; Xia, Ningshao; Tang, Qiyi; Cheng, Tong (2019). A rapid neutralization testing system for Zika virus based on an enzyme-linked immunospot assay. ACS Infectious Diseases, (), acsinfecdis.9b00333–. doi:10.1021/acsinfecdis.9b00333
Shanghai Novopathway Biotechnology
Building No.5, East Huaxia Road No.333, Pudong New Area, Shanghai
BD Cooperation Email: BD@novopathway.com Tel: 021-5838 0618-501
Join Us Email: HR@novopathway.com Tel: 021-5838 0356
Beijing Sun-Novo Pharmaceutical Research
Building No.7, West Shuangying Road No.79 , Changping Area, Beijing
Website: http://www.sun-novo.com